F. Stephen Hodi Jr., MD

F. Stephen Hodi Jr., MD

Medical Oncology

Contact Information

Office Phone Number

617-632-5055 (Melanoma Disease Center)
617-632-2563 (Center for Immuno-Oncology)

Fax

617-632-6727

Appointments

617-632-6869 (new)

Biography

F. Stephen Hodi Jr., MD

Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Brigham Cancer Center and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi competed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania, and Medical Oncology training at Dana-Farber cancer Institute where he joined the faculty in 1995. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the International Society for the Biological Therapy of cancer, and a founding member of the Society for Melanoma Research.

Researcher

Physician

Director, Melanoma Center
Director, Center for Immuno-Oncology
Sharon Crowley Martin Chair in Melanoma
Professor of Medicine, Harvard Medical School

Clinical Interests

Gene therapy for cancer, Melanoma, Tumor immunology

Diseases Treated

Board Certification

  • Internal Medicine, 1995
  • Medical Oncology, 1997

Fellowship

  • Dana-Farber Cancer Institute, Medical Oncology

Residency

  • University of Pennsylvania School of Medicine, Internal Medicine

Medical School

  • Weill Medical College of Cornell University

Recent Awards

  • Mentoring Clinical Scientist Development Award 1998

Research

    Combination Immunotherapies for Cancer

    The ability to manipulate genes that encode potential immunomodulators, such as cytokines and tumor antigens, has opened a new era of research. Poorly immunogenic murine tumor systems demonstrate that vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) generates potent, specific, and long-lasting immunity. To test this strategy in patients with advanced melanoma, our laboratory performed a clinical trial of vaccination with lethally irradiated, autologous melanoma cells expressing human GM-CSF. Vaccination elicited a striking infiltrate of large numbers of lymphocytes, plasma cells, macrophages, and eosinophils, resulting in tumor destruction, fibrosis, and edema. These results provide a solid foundation for undertaking a molecular analysis of the melanoma antigens stimulating specific T and B cell responses in vaccinated patients. Candidate antigens are identified from screening with autologous sera of a complementary DNA expression library constructed from vaccinated patients' tumor cell lines. For a number of antigens evaluated, potent humoral immune responses are associated with immune-mediated destruction of diverse tumors - offering the promise of future antigen-directed therapies.One mechanism that may limit the therapeutic potency of cancer vaccines is the attenuation of T cell function by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Striking therapeutic synergies have been observed between CTLA-4 blockade and GM-CSF-secreting tumor cell vaccines in murine models of melanoma, breast cancer, and prostate cancer. Based on these preclinical data, we initiated a phase I clinical trial of single administration of anti-CTLA-4 antibody (MDX-CTLA-4) in previously vaccinated patients with metastatic melanoma or ovarian cancer. Of the nine subjects treated, three had received irradiated, autologous GM-CSF-secreting melanoma cells; four patients with metastatic melanoma had received vaccinations against melanosomal antigens; and two patients with ovarian cancer had received autologous GM-CSF-secreting cells. The three patients who received autologous GM-CSF-secreting melanoma cell vaccines demonstrated extensive tumor necrosis associated with hemorrhage and immune infiltrates in response to MDX-CTLA-4. In contrast, four of four patients who received vaccinations for melanosomal antigens failed to develop an immune infiltrate or tumor necrosis in response to MDX-CTLA4. The two patients with ovarian cancer had either a decrease or plateau to their CA-125 tumor marker levels following treatment with MDX-CTLA-4.The immune infiltrates and massive tumor destruction witnessed in patients who had received MDX-CTLA-4 and GM-CSF-secreting cell vaccines suggest synergistic antitumor effects. This work provides the basis for additional studies to verify these observations in additional tumor types and to test combination immunotherapy modalities.

    Publications

      • Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Cancer Immunol Immunother. 2024 Jan 18; 73(1):17. View in: Pubmed

      • Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 Dec 19; 3(12):2572-2584. View in: Pubmed

      • Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023 Dec 04. View in: Pubmed

      • EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade. Cancer Immunol Res. 2023 11 01; 11(11):1493-1507. View in: Pubmed

      • Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 01; 9(11):1574-1582. View in: Pubmed

      • Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials. Cancer Epidemiol Biomarkers Prev. 2023 11 01; 32(11):1552-1557. View in: Pubmed

      • Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023 Nov; 29(11):2737-2741. View in: Pubmed

      • The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials. Cancer. 2024 Feb 01; 130(3):439-452. View in: Pubmed

      • Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade. Cancer Immunol Res. 2023 08 03; 11(8):1100-1113. View in: Pubmed

      • Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw. 2023 08; 21(8):831-840.e3. View in: Pubmed

      • Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2023 06 13; 29(12):2336. View in: Pubmed

      • A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Front Oncol. 2022; 12:975642. View in: Pubmed

      • Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. J Natl Compr Canc Netw. 2023 06; 21(6):617-626.e3. View in: Pubmed

      • Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry. Lab Invest. 2023 08; 103(8):100174. View in: Pubmed

      • Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy. J Immunother. 2023 06 01; 46(5):192-196. View in: Pubmed

      • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

      • Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. 2023 04 10; 41(4):791-806.e4. View in: Pubmed

      • Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis. ACG Case Rep J. 2023 Mar; 10(3):e01018. View in: Pubmed

      • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol. 2023 02 10; 41(5):943-954. View in: Pubmed

      • Impact of Precision Medicine in Oncology: Immuno-oncology. Cancer J. 2023 Jan-Feb 01; 29(1):15-19. View in: Pubmed

      • Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II Expression. Cancer Immunol Res. 2022 12 02; 10(12):1559-1569. View in: Pubmed

      • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023 02 01; 129(3):367-375. View in: Pubmed

      • Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells. Cell Mol Bioeng. 2022 Dec; 15(6):535-551. View in: Pubmed

      • Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022 10 10; 40(10):1161-1172.e5. View in: Pubmed

      • Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196. View in: Pubmed

      • Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540. View in: Pubmed

      • First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 08 15; 28(16):3452-3463. View in: Pubmed

      • Mechanical checkpoint regulates monocyte differentiation in fibrotic niches. Nat Mater. 2022 08; 21(8):939-950. View in: Pubmed

      • Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413. View in: Pubmed

      • Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling. Immunotherapy. 2022 08; 14(11):843-850. View in: Pubmed

      • Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253. View in: Pubmed

      • Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun. 2022 May; 2(5):390. View in: Pubmed

      • Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply. N Engl J Med. 2022 05 12; 386(19):1860-1861. View in: Pubmed

      • Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials. STAR Protoc. 2022 06 17; 3(2):101362. View in: Pubmed

      • Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers (Basel). 2022 May 05; 14(9). View in: Pubmed

      • GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194. View in: Pubmed

      • Reply to T. Olivier et al. J Clin Oncol. 2022 05 10; 40(14):1597-1598. View in: Pubmed

      • Mass cytometry staining for human bone marrow clinical samples. STAR Protoc. 2022 03 18; 3(1):101163. View in: Pubmed

      • Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688. View in: Pubmed

      • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291. View in: Pubmed

      • Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 01 06; 386(1):24-34. View in: Pubmed

      • Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022 03; 75(3):531-540. View in: Pubmed

      • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022 01 10; 40(2):127-137. View in: Pubmed

      • Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021 11 23; 5(22):4701-4709. View in: Pubmed

      • Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 12; 22(12):1740-1751. View in: Pubmed

      • Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 12; 22(12):1692-1704. View in: Pubmed

      • SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. Cancer Res. 2021 12 15; 81(24):6131-6141. View in: Pubmed

      • Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 11 02; 23(11):1961-1973. View in: Pubmed

      • Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun. 2021 10; 1(1):30-40. View in: Pubmed

      • Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318. View in: Pubmed

      • Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. 2021 11; 157:391-402. View in: Pubmed

      • Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. Eur J Cancer. 2021 11; 157:493-510. View in: Pubmed

      • Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021 09 16; 184(19):4996-5014.e26. View in: Pubmed

      • Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021 12; 32(12):1597-1607. View in: Pubmed

      • Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940. View in: Pubmed

      • TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunol Res. 2021 10; 9(10):1202-1213. View in: Pubmed

      • Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. NPJ Precis Oncol. 2021 Jun 29; 5(1):62. View in: Pubmed

      • Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217. View in: Pubmed

      • CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):4025-4035. View in: Pubmed

      • Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5). View in: Pubmed

      • Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3620-3629. View in: Pubmed

      • The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res. 2021 04 01; 31(2):181-185. View in: Pubmed

      • Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 04; 10(8):2627-2635. View in: Pubmed

      • Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364. View in: Pubmed

      • Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 06; 11(6):1524-1541. View in: Pubmed

      • A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 05 01; 27(9):2470-2480. View in: Pubmed

      • A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma?. ESMO Open. 2021 04; 6(2):100050. View in: Pubmed

      • Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 02 01; 31(1):67-75. View in: Pubmed

      • A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654. View in: Pubmed

      • Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Aug; 70(8):2209-2221. View in: Pubmed

      • Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 05 15; 27(10):2773-2781. View in: Pubmed

      • Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 09 15; 27(18):5038-5048. View in: Pubmed

      • Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021 02; 144:182-191. View in: Pubmed

      • A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205. View in: Pubmed

      • Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2021 Jan 11; 39(1):122. View in: Pubmed

      • Author Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Dec; 20(12):757. View in: Pubmed

      • Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380. View in: Pubmed

      • Preface. Hematol Oncol Clin North Am. 2021 02; 35(1):ix-x. View in: Pubmed

      • Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 12 15; 126(24):5274-5282. View in: Pubmed

      • Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 10 12; 38(4):500-515.e3. View in: Pubmed

      • Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precis Oncol. 2020; 4. View in: Pubmed

      • Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer. 2020 12 01; 126(23):5088-5097. View in: Pubmed

      • Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. View in: Pubmed

      • Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637. View in: Pubmed

      • High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. STAR Protoc. 2020 09 18; 1(2):100055. View in: Pubmed

      • Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 10 01; 26(19):5086-5091. View in: Pubmed

      • Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22. View in: Pubmed

      • Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. View in: Pubmed

      • Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. J Clin Oncol. 2020 08 10; 38(23):2667-2676. View in: Pubmed

      • Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020 06 18; 5(12). View in: Pubmed

      • Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 09; 16(9):e933-e942. View in: Pubmed

      • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. View in: Pubmed

      • Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311. View in: Pubmed

      • Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084. View in: Pubmed

      • Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. J Biol Methods. 2020; 7(2):e131. View in: Pubmed

      • Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020 04; 19(4):1031-1039. View in: Pubmed

      • Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572. View in: Pubmed

      • Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575. View in: Pubmed

      • Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 Apr; 30(4):589-596. View in: Pubmed

      • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019 Apr; 30(4):582-588. View in: Pubmed

      • Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 Nov; 20(11):1556. View in: Pubmed

      • Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019 Oct 01; 5(10):1411-1420. View in: Pubmed

      • Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546. View in: Pubmed

      • Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358. View in: Pubmed

      • Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 Aug; 25(8):1319. View in: Pubmed

      • Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072. View in: Pubmed

      • Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. Cancer Immunol Immunother. 2019 Aug; 68(8):1331-1340. View in: Pubmed

      • Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):936-940. View in: Pubmed

      • Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935. View in: Pubmed

      • Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. J Biol Methods. 2019; 6(2):e114. View in: Pubmed

      • Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:165-174. View in: Pubmed

      • The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. Cancer Immunol Res. 2019 07; 7(7):1214-1220. View in: Pubmed

      • Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112. View in: Pubmed

      • The Intersection between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res. 2019 09 15; 25(18):5449-5457. View in: Pubmed

      • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019 04 01; 30(4):582-588. View in: Pubmed

      • Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596. View in: Pubmed

      • Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. View in: Pubmed

      • Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 03; 20(3):326-336. View in: Pubmed

      • Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019 06 01; 25(11):3220-3228. View in: Pubmed

      • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2019 02 01; 40(1):17-65. View in: Pubmed

      • irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184. View in: Pubmed

      • Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunol Res. 2019 03; 7(3):458-465. View in: Pubmed

      • Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. View in: Pubmed

      • Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610. View in: Pubmed

      • Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology. 2019 01; 290(1):9-22. View in: Pubmed

      • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: Pubmed

      • Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients. Cell Tissue Bank. 2018 Dec; 19(4):783-790. View in: Pubmed

      • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1480-1492. View in: Pubmed

      • Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas. 2018 10; 47(9):1123-1129. View in: Pubmed

      • The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. View in: Pubmed

      • Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 09; 119(6):670-674. View in: Pubmed

      • Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018 Dec; 67(12):1833-1844. View in: Pubmed

      • Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281. View in: Pubmed

      • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730. View in: Pubmed

      • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018 08 09; 174(4):1031-1032. View in: Pubmed

      • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 09; 101:114-122. View in: Pubmed

      • MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018 07 18; 10(450). View in: Pubmed

      • Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045. View in: Pubmed

      • An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44. View in: Pubmed

      • Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 10 15; 24(20):4960-4967. View in: Pubmed

      • Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8. View in: Pubmed

      • Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunol Res. 2018 06; 6(6):630-635. View in: Pubmed

      • Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018 04 04; 6(1):26. View in: Pubmed

      • Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Res. 2018 04; 28(2):89-95. View in: Pubmed

      • Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018 Mar 30; 359(6383):1537-1542. View in: Pubmed

      • Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology. 2018; 7(7):e1440930. View in: Pubmed

      • Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer. 2018 03 06; 6(1):18. View in: Pubmed

      • Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):173-182. View in: Pubmed

      • Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815. View in: Pubmed

      • Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858. View in: Pubmed

      • Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806. View in: Pubmed

      • Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018 03 15; 124(6):1111-1121. View in: Pubmed

      • Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e20-e32. View in: Pubmed

      • Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674. View in: Pubmed

      • Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis. 2018 Mar; 5(1):46-48. View in: Pubmed

      • Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. View in: Pubmed

      • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340. View in: Pubmed

      • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45. View in: Pubmed

      • Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol. 2017 Nov 01; 3(11):1511-1519. View in: Pubmed

      • Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res. 2017 12; 5(12):1133-1140. View in: Pubmed

      • Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res. 2017 11; 5(11):1046-1055. View in: Pubmed

      • Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16. View in: Pubmed

      • Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822. View in: Pubmed

      • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 10 05; 377(14):1345-1356. View in: Pubmed

      • Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430. View in: Pubmed

      • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10. View in: Pubmed

      • Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 01; 35(34):3807-3814. View in: Pubmed

      • Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017; 5:66. View in: Pubmed

      • Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017 08 15; 5(1):66. View in: Pubmed

      • A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017 Aug; 6(8):1904-1914. View in: Pubmed

      • Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210. View in: Pubmed

      • Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744. View in: Pubmed

      • Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017 Nov; 14(11):655-668. View in: Pubmed

      • Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. View in: Pubmed

      • Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 09; 82:80-91. View in: Pubmed

      • Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. View in: Pubmed

      • Risk of Bias and Heterogeneity-Reply. JAMA Oncol. 2017 06 01; 3(6):858-859. View in: Pubmed

      • Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 01; 28(6):1380-1387. View in: Pubmed

      • Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. Cytotechnology. 2018 Feb; 70(1):1-11. View in: Pubmed

      • Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2017; 1. View in: Pubmed

      • Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 06; 5(6):480-492. View in: Pubmed

      • Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017 06; 22(6):709-718. View in: Pubmed

      • Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunol Res. 2017 06; 5(6):446-454. View in: Pubmed

      • Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221. View in: Pubmed

      • Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290. View in: Pubmed

      • Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. View in: Pubmed

      • Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res. 2017 04; 5(4):286-291. View in: Pubmed

      • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 03; 18(3):e143-e152. View in: Pubmed

      • Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318. View in: Pubmed

      • Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. View in: Pubmed

      • Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15; 23(14):3510-3519. View in: Pubmed

      • Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351. View in: Pubmed

      • Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget. 2017 Jan 24; 8(4):6873-6882. View in: Pubmed

      • Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol. 2017 Jan-Feb; 18(1):42-53. View in: Pubmed

      • Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res. 2017 01; 5(1):17-28. View in: Pubmed

      • Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4:84. View in: Pubmed

      • Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Lab Invest. 2017 02; 97(2):207-216. View in: Pubmed

      • Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 01; 2(12):1607-1616. View in: Pubmed

      • Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048. View in: Pubmed

      • Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017 Mar; 35(7):785-792. View in: Pubmed

      • PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. Br J Haematol. 2018 03; 180(5):752-755. View in: Pubmed

      • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol. 2017 Jan 10; 35(2):226-235. View in: Pubmed

      • Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109. View in: Pubmed

      • An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 01; 22(21):5204-5210. View in: Pubmed

      • Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017 04 15; 23(8):1929-1936. View in: Pubmed

      • A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050. View in: Pubmed

      • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016 11 10; 375(19):1845-1855. View in: Pubmed

      • Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. Pigment Cell Melanoma Res. 2016 11; 29(6):656-668. View in: Pubmed

      • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1558-1568. View in: Pubmed

      • Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016 09 08; 1(14):e89014. View in: Pubmed

      • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 08 30; 7:12624. View in: Pubmed

      • VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res. 2016 10; 4(10):858-868. View in: Pubmed

      • PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060. View in: Pubmed

      • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. View in: Pubmed

      • Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016; 4:44. View in: Pubmed

      • Reply to M. Nishino. J Clin Oncol. 2016 10 01; 34(28):3481. View in: Pubmed

      • Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016; 4:42. View in: Pubmed

      • Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. View in: Pubmed

      • Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393. View in: Pubmed

      • Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60. View in: Pubmed

      • Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32. View in: Pubmed

      • Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87. View in: Pubmed

      • Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 06 16; 1(9):e87415. View in: Pubmed

      • Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 09; 90(3):638-47. View in: Pubmed

      • Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul; 17(7):943-955. View in: Pubmed

      • Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016 07; 48(7):725-32. View in: Pubmed

      • RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer. 2016 07; 62:138-45. View in: Pubmed

      • RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016 07; 62:132-7. View in: Pubmed

      • Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 08; 66(8):1463-1473. View in: Pubmed

      • Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016 07 01; 22(13):3127-31. View in: Pubmed

      • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. View in: Pubmed

      • Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22. View in: Pubmed

      • Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol. 2016 Apr; 40(4):443-53. View in: Pubmed

      • Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73. View in: Pubmed

      • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7. View in: Pubmed

      • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501. View in: Pubmed

      • Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2016 Apr; 4(4):289-93. View in: Pubmed

      • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008. View in: Pubmed

      • Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol. 2016 Feb; 13(2):77-8. View in: Pubmed

      • Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35. View in: Pubmed

      • Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan; 4(1):12-7. View in: Pubmed

      • CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology. Clin Cancer Res. 2015 Nov 15; 21(22):4989-91. View in: Pubmed

      • PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15. View in: Pubmed

      • Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35. View in: Pubmed

      • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 09 24; 373(13):1270-1. View in: Pubmed

      • Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. View in: Pubmed

      • Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015 Sep; 125(9):3377-83. View in: Pubmed

      • Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15. View in: Pubmed

      • Corticosteroids and immune checkpoint blockade. Aging (Albany NY). 2015 Aug; 7(8):521-2. View in: Pubmed

      • Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015 Jul 16; 373(3):288-90. View in: Pubmed

      • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. View in: Pubmed

      • Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92. View in: Pubmed

      • Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015 Jun 20; 33(18_suppl):LBA1. View in: Pubmed

      • Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015; 7:59. View in: Pubmed

      • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 02; 373(1):23-34. View in: Pubmed

      • A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028. View in: Pubmed

      • Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8. View in: Pubmed

      • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63. View in: Pubmed

      • Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64. View in: Pubmed

      • A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist. 2015 Jun; 20(6):617-8. View in: Pubmed

      • Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91. View in: Pubmed

      • Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-12. View in: Pubmed

      • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21; 372(21):2006-17. View in: Pubmed

      • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015 Jun 20; 33(18):2013-20. View in: Pubmed

      • Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86. View in: Pubmed

      • Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015 Jul; 84(7):1259-68. View in: Pubmed

      • Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2015 May; 28(3):357-9. View in: Pubmed

      • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr; 16(4):375-84. View in: Pubmed

      • Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96. View in: Pubmed

      • Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3. View in: Pubmed

      • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015 Jun 10; 33(17):1889-94. View in: Pubmed

      • The use of granulocyte-macrophage colony-stimulating factor in melanoma treatment. Clin Adv Hematol Oncol. 2015 Feb; 13(2):84-6. View in: Pubmed

      • Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817. View in: Pubmed

      • Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15(12):1389-403. View in: Pubmed

      • Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15; 21(4):749-55. View in: Pubmed

      • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27; 515(7528):563-7. View in: Pubmed

      • Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; 2(1):40. View in: Pubmed

      • Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30. View in: Pubmed

      • Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma. Cancer Immunol Res. 2015 Jan; 3(1):59-67. View in: Pubmed

      • Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53. View in: Pubmed

      • Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. View in: Pubmed

      • Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. View in: Pubmed

      • PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184. View in: Pubmed

      • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. View in: Pubmed

      • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014 Oct; 40(9):1056-64. View in: Pubmed

      • Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12. View in: Pubmed

      • The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun 22; 9:143. View in: Pubmed

      • Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA9000. View in: Pubmed

      • Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2:17. View in: Pubmed

      • Hematology/Oncology Clinics of North America. Melanoma. Preface. Hematol Oncol Clin North Am. 2014 Jun; 28(3):xiii-xiv. View in: Pubmed

      • Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9. View in: Pubmed

      • Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54. View in: Pubmed

      • Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42. View in: Pubmed

      • Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. J Clin Oncol. 2015 Feb 20; 33(6):e32-5. View in: Pubmed

      • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 01; 32(10):1020-30. View in: Pubmed

      • Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 01; 120(11):1695-701. View in: Pubmed

      • Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2014 02; 2(2):127-32. View in: Pubmed

      • A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24. View in: Pubmed

      • Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013 Dec 30; 13(4):626-32. View in: Pubmed

      • Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21. View in: Pubmed

      • Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014 Jan; 2(1):15-8. View in: Pubmed

      • CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 01; 19(19):5300-9. View in: Pubmed

      • Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. View in: Pubmed

      • Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16. View in: Pubmed

      • The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98. View in: Pubmed

      • Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. View in: Pubmed

      • Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013 Jun 20; 31(18_suppl):CRA9006. View in: Pubmed

      • Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90. View in: Pubmed

      • Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 1291:1-13. View in: Pubmed

      • Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013 Jun; 18(6):733-43. View in: Pubmed

      • Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936-43. View in: Pubmed

      • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. View in: Pubmed

      • Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32. View in: Pubmed

      • Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist. 2013 Jun; 18(6):717-25. View in: Pubmed

      • Treatment for advanced melanoma: new drugs, new opportunities, new challenges. Oncology (Williston Park). 2013 May; 27(5):381-92, 391. View in: Pubmed

      • Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 04; 368(14):1365-6. View in: Pubmed

      • Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):395-407. View in: Pubmed

      • The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013 Mar; 2(1):7. View in: Pubmed

      • Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013 Apr 15; 19(8):2232-9. View in: Pubmed

      • Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One. 2013; 8(2):e56134. View in: Pubmed

      • Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013 May 01; 119(9):1675-82. View in: Pubmed

      • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31. View in: Pubmed

      • The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013 Feb 01; 19(3):598-609. View in: Pubmed

      • Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012 Dec 15; 18(24):6580-7. View in: Pubmed

      • When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012 Oct 17; 104(20):1534-41. View in: Pubmed

      • Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. View in: Pubmed

      • Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA2509. View in: Pubmed

      • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28; 366(26):2443-54. View in: Pubmed

      • Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-?B pathways. Mol Cancer Ther. 2012 Sep; 11(9):1905-14. View in: Pubmed

      • From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61. View in: Pubmed

      • c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32. View in: Pubmed

      • Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May; 13(5):459-65. View in: Pubmed

      • Melanoma. J Natl Compr Canc Netw. 2012 Mar; 10(3):366-400. View in: Pubmed

      • Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6. View in: Pubmed

      • The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One. 2012; 7(1):e29622. View in: Pubmed

      • Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. View in: Pubmed

      • Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 01; 18(1):9-14. View in: Pubmed

      • Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother. 2012 May; 61(5):655-65. View in: Pubmed

      • Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol. 2011 Aug; 197(2):W241-6. View in: Pubmed

      • A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8511. View in: Pubmed

      • Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8508. View in: Pubmed

      • Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol. 2011 May 20; 29(15_suppl):8581. View in: Pubmed

      • Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34. View in: Pubmed

      • Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15; 17(14):4622-8. View in: Pubmed

      • Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. View in: Pubmed

      • Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010 Sep 22; 102(18):1388-97. View in: Pubmed

      • Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol. 2010 Sep; 8(9):619-27. View in: Pubmed

      • A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. 2010 Jun 20; 28(18_suppl):4. View in: Pubmed

      • Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23. View in: Pubmed

      • Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83. View in: Pubmed

      • The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol. 2010 Apr; 37 Suppl 1:48-53. View in: Pubmed

      • Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010 Mar; 6 Suppl 1:S16-23. View in: Pubmed

      • Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010 Jan 15; 70(2):697-708. View in: Pubmed

      • Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26. View in: Pubmed

      • Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 01; 15(23):7412-20. View in: Pubmed

      • Melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):250-75. View in: Pubmed

      • Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 01; 14(23):7726-32. View in: Pubmed

      • KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008 Nov 01; 14(21):6821-8. View in: Pubmed

      • Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol. 2008 Dec; 5(12):696-7. View in: Pubmed

      • Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008 Aug; 32(8):1130-7. View in: Pubmed

      • CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008 Sep; 5(9):557-61. View in: Pubmed

      • Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905. View in: Pubmed

      • Genomic alterations of KIT in acral and mucosal melanomas. J Clin Oncol. 2008 May 20; 26(15_suppl):9016. View in: Pubmed

      • Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol. 2008 May 20; 26(15_suppl):3007. View in: Pubmed

      • Prolonged survival in objective responders to ipilimumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):20004. View in: Pubmed

      • Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol. 2008 May 20; 26(15_suppl):3008. View in: Pubmed

      • Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85. View in: Pubmed

      • Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51. View in: Pubmed

      • Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008 Apr; 222:287-98. View in: Pubmed

      • Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr; 7(4):1490-9. View in: Pubmed

      • Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10. View in: Pubmed

      • Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73. View in: Pubmed

      • Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5238-42. View in: Pubmed

      • Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67. View in: Pubmed

      • High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. View in: Pubmed

      • Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med. 2007 Jan 18; 356(3):285-92. View in: Pubmed

      • Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9190-5. View in: Pubmed

      • Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):673-8. View in: Pubmed

      • Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in previously vaccinated melanoma and ovarian cancer patients. Keystone Symposia: Advances in the understanding and treatment of melanoma. 2006. View in: Pubmed

      • Combinatorial cancer immunotherapy. Adv Immunol. 2006; 90:341-68. View in: Pubmed

      • Combinatorial Cancer Immunotherapy. in Cancer Immunotherapy – a thematic volume of Advances in Immunology. Elsevier Academic Press. 2006; 90:341-368. View in: Pubmed

      • Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101. View in: Pubmed

      • Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 01; 11(21):7692-9. View in: Pubmed

      • Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005 May 19; 5:7. View in: Pubmed

      • Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. View in: Pubmed

      • Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). J Clin Oncol. 2004 Jul 15; 22(14_suppl):2536. View in: Pubmed

      • Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Proceedings of ASCO. 2004. View in: Pubmed

      • Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3343-50. View in: Pubmed

      • Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7. View in: Pubmed

      • MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3. View in: Pubmed

      • Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. View in: Pubmed

      • Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30. View in: Pubmed

      • Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. Journal of Clinical Oncology. 2003; 21:624-630. View in: Pubmed

      • The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3398-3403. View in: Pubmed

      • Vaccination with Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony Stimulating Factor by Adenoviral Mediated Gene Transfer Augments Anti-tumor Immunity in Patients with Metastatic Melanoma. Journal of Clinical Oncology. 2003; 21:3343-3350. View in: Pubmed

      • Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002 Sep 15; 100(6):2123-31. View in: Pubmed

      • Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol. 2002 Jun; 138(6):799-802. View in: Pubmed

      • Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6. View in: Pubmed

      • ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24. View in: Pubmed

      • Skin cancer. in Atlas of Diagnostic Oncology. 2002; 364-394. View in: Pubmed

      • Interleukins and Cancer. in Encyclopedia of Cancer. 2002; 523-535. View in: Pubmed

      • Identification of novel antigens in chronic lymphocytic leukemia by SEREX: Assessment of their potential as targets for immunotherapeutic approaches. Blood. 2002; 100:2123-2131. View in: Pubmed

      • A phase I/II trial utilizing autologous dendritic cells transduced with gp100 and Melan A/MART-1-encoding adenoviruses in advanced melanoma. Proceedings of ASH. 2001. View in: Pubmed

      • Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45. View in: Pubmed

      • Adjuvant high-dose interferon Alpha-2b in patients with high-risk melanoma. Cancer J Sci Am. 2000; 6:139-45.. View in: Pubmed

      • Immunologic Gene Therapy of Melanoma: Phase I Study of Therapy with Autologous Dendritic Cells Transduced with Recombinant Adenoviruses Encoding Melanoma Antigens. Proceedings of ASCO. 2000. View in: Pubmed

      • Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. Proceedings of ASCO. 1999. View in: Pubmed

      • Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6. View in: Pubmed

      • Genetically modified tumor cell vaccines. Surg Oncol Clin N Am. 1998 Jul; 7(3):471-85. View in: Pubmed

      • Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb; 16(2):670-82. View in: Pubmed

      • Genetically-modified tumor vaccines. Surgical Oncology Clinics of North America. 1998; 7:471-485. View in: Pubmed

      • The molecular genetics of familial malignant melanoma. Journal of Clinical Oncology. 1998; 16:670-682. View in: Pubmed

      • Gender as a factory influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, Germany. 1995. View in: Pubmed

      • Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Genoa, Italy. Second International Conference on Geriatric Oncology. 1994. View in: Pubmed

      • High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer. Prog Clin Biol Res. 1994; 389:487-95. View in: Pubmed

      • A plea for prices in physician prescribing. JAMA. 1991 Dec 18; 266(23):3285. View in: Pubmed

      • Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products. J Immunol. 1990 May 15; 144(10):3726-35. View in: Pubmed

      • Use of cDNA probes specific for the human MHC class II beta loci for tissue-typing nonhuman primates at their class II beta loci. Transplantation. 1989 Jul; 48(1):170-3. View in: Pubmed

      • A primate species with limited major histocompatibility complex class I polymorphism. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7714-8. View in: Pubmed

      • Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer. 1988 Apr 15; 41(4):601-8. View in: Pubmed

      • Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys. International Journal of Cancer. 1988; 41:601-8. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 540 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 540 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      F. Stephen Hodi Jr., MD

      About Our Ratings

      Physician Star Rating Comment Block